Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04120480 · ClinicalTrials.gov registry record · NA

Effectiveness of PGx Testing

A NA study of Polypharmacy, sponsored by Kaiser Permanente.

Active
Registry status
NA
Development phase
600
Enrollment target
1
Study location

NCT04120480 is a NA study of Polypharmacy that is active but no longer recruiting, run by Kaiser Permanente. The registered enrollment target is 600 participants, below the 1,526-participant average among 8 other Polypharmacy trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04120480, a NA study of Polypharmacy, is active but no longer recruiting, sponsored by Kaiser Permanente.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the clinical and economic effectiveness of a pharmacogenomic (PGx) approach to prescribing medications in patients with high-risk polypharmacy in an integrated healthcare delivery system. Investigators hypothesize that patients who receive the RightMed® PGx test from OneOme, LLC with subsequent counseling of their prescribers by a study pharmacist, as needed, on the appropriateness of their prescribed medications will experience lower one-year follow-up healthcare utilization and expenditures compared to control patients who receive usual care.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Pharmacogenomic test

Study Locations (1)

Colorado

  • Central Support Services - Aurora

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2019-11-15
Est. Completion 2027-12-31
Phase NA

Sponsor

Kaiser Permanente

294 total trials

What the Registry Record Tells You About NCT04120480

The ClinicalTrials.gov registry entry for NCT04120480 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,526-participant average among 8 other Polypharmacy trials with a reported enrollment target (61% lower). The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Polypharmacy appearing as the primary indexed condition, and to 1 intervention - of which Pharmacogenomic test is the first listed.

NCT04120480 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT04120480 about?

NCT04120480 is a clinical study titled "Effectiveness of PGx Testing". The purpose of this study is to determine the clinical and economic effectiveness of a pharmacogenomic (PGx) approach to prescribing medications in patients with high-risk polypharmacy in an integrated healthcare delivery system. Investigators hypothesize that patients who receive the RightMed® PGx...

What is the current status of trial NCT04120480?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2019-11-15. Estimated completion is 2027-12-31.

What conditions does trial NCT04120480 study?

This clinical trial studies the following conditions: Polypharmacy.

What interventions are being tested in trial NCT04120480?

The interventions under investigation include: Pharmacogenomic test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04120480?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04120480 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Polypharmacy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.